

IN THE CLAIMS:

Please cancel Claims 3, 8-17, 20 and 21.

Please amend Claims 1, 2, 4-7, 18 and 19 as

follows:

Sub D' ↗

1. (Amended) An isolated DNA [related to IgA nephronopathy] comprising a nucleotide sequence selected from the group of nucleotide sequences [represented by] consisting of SEQ ID NO:1-6 and 9-12 [to NO:32 and SEQ ID NO:39 to NO:42], or

A ↗  
a DNA which hybridizes with said DNA [under stringent conditions] at 65°C in the presence of 0.7-1.0M NaCl using a filter on which said DNA is immobilized followed by washing the filter with 0.1 x to 2 x SSC solution (where 1 x SSC is 150 mM sodium chloride and 15 mM sodium citrate) at 65°C.

Sub B' ↗

2. (Amended) An isolated DNA comprising a nucleotide sequence identical to any continuous 5 to 60 residues in a nucleotide sequence selected from the nucleotide sequences [represented by] consisting of the 1<sup>st</sup> to the 1894<sup>th</sup> nucleotide of SEQ ID NO:1 [to NO:32 and SEQ ID NO:39 to NO: 42], the 1<sup>st</sup> to the 2644<sup>th</sup> nucleotide of SEQ ID

a1  
NO:2, the 116<sup>th</sup> to the 2981<sup>st</sup> nucleotide of SEQ ID NO: 3, the 1<sup>st</sup> to the 1415<sup>th</sup> nucleotide of SEQ ID NO:4, the 1<sup>st</sup> to the 2666<sup>th</sup> nucleotide of SEQ ID NO:5, the 1<sup>st</sup> to the 2244<sup>th</sup> nucleotide of SEQ ID NO:6, the 31<sup>st</sup> to the 135<sup>th</sup> nucleotide of SEQ ID NO:9, the 1<sup>st</sup> to the 93<sup>rd</sup> nucleotide of SEQ ID NO:10, the 48<sup>th</sup> to the 137<sup>th</sup> nucleotide of SEQ ID NO:11, and the 1<sup>st</sup> to the 193<sup>rd</sup> nucleotide of SEQ ID NO:12, or

a DNA comprising a sequence complementary to said DNA.

Sub D<sup>2</sup>

4. (Amended) A method for detecting mRNA [of an IgA nephropathy-related gene] using the DNA according to any one of claims 1 [to 3] or 2.

a2  
5. (Amended) An IgA nephropathy diagnostic agent comprising the DNA according to any one of claims 1 [to 3] or 2.

6. (Amended) A method for inhibiting transcription of a[n IgA nephropathy-related] gene or translation of mRNA of a[n IgA nephropathy-related] gene using the DNA according to claim 2 [or 3].

A<sup>2</sup> Sub B<sup>2</sup>

7. (Amended) A[n] method of treating IgA nephropathy [therapeutic agent] comprising administering the [DNA] composition according to claim [2 or 3] 19.

Sub D<sup>3</sup>

18. (Amended) A composition comprising the DNA according to any one of claims 1 [to 3] or 2 and a diagnostic acceptable carrier.

A<sup>3</sup>

19. (Amended) A composition comprising the DNA according to claim 2 [or 3] and a pharmaceutical acceptable carrier.

#### REMARKS

Claims 1 and 2 have been amended in order to recite the present invention with the specificity required by statute. Additionally, Claims 4-7, 18 and 19 have been amended for better conformity with accepted U.S. practice and/or to better depend from their antecedent claims. The subject matter of the amendment may be found in the specification as filed, *inter alia*, at page 7, lines 1-5. Accordingly, no new matter has been added.

The Examiner has required that Applicants affirm their provisional Election and Selection of Species. By the